Value based pricing will not fit with reference pricing, says UK's ABPI
This article was originally published in SRA
Executive Summary
Value based pricing systems and reference pricing will be incompatible in the long run, Richard Barker, director general of the Association of the British Pharmaceutical Industry, told a press conference yesterday1. "They are not going to be comfortable bedfellows," he said.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.